Vésale Bioscience (Inteliphage)

Vésale is the leader in personalized phage therapy, providing a safe and efficacious solution to the second largest cause of death globally: Difficult-to-Treat Infections ("DTI").  13.7 million infection-related deaths in 2019, of which 4.2 million deaths (30.9%) associated with the top 5 bacterial pathogens (both resistant and susceptible to antibiotics).

Vésale has developed the Phagogram, a unique susceptibility test which makes a scalable and profitable personalized treatment possible and efficacious, thanks to its unique features: it is fast, automated, on-site and easy-to-use, without the need for human interpretation of results. With its large and ever-growing phage library, and its GMP production unit, Vésale is already able to successfully treat a very significant portion of the 250,000 last-hope patients (EU5 + BeNeLux only) with infections caused by the 4 ESKP bacteria (S.a, P.a, K.p, E.c).

Why invest in phage therapy now? Because the regulatory pathway for personalized phage therapy is now clear and confirmed by regulatory authorities for last-hope patients in Europe without any need for clinical trials, and because the new draft European regulation is providing a favorable marketing authorization pathway designed to promote personalized phage therapy, fully aligned with our business model and clinical strategy.